ArticleAddiction science & clinical practice2025
Patient-elected low-dose intravenous naloxone for rapid buprenorphine induction: a case report.
Article in Addiction science & clinical practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Retention in Telehealth-Delivered Buprenorphine Treatment for Opioid Use Disorder: Multistate Retrospective Cohort Study.Journal of medical Internet research · 2026Article
- The Buprenorphine Paradox: How Buprenorphine Triggers and Resolves Opioid Withdrawal.Addiction biology · 2026Article
- Naloxone dosing: An evolving unregulated drug landscape, care setting considerations, and the need for research.Addiction (Abingdon, England) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBuprenorphine is a common partial opioid agonist treatment for opioid use disorder (OUD). Despite its efficacy, major challenges to induction include the significant time consumption and the difficult requirement for patients to be in moderate opioid withdrawal. CASE PRESENTATION: We present the case of a 31-year-old man with severe OUD and regular fentanyl use who was successfully initiated on buprenorphine-naloxone using low-dose intravenous naloxone in ten minutes and administered 300 mg of extended-release injectable buprenorphine within two hours. This involved the rapid administration of small doses of intravenous naloxone with an assessment of withdrawal symptoms after each dose. Buprenorphine-naloxone is immediately administered once moderate withdrawal is reached.
conclusionsLow-dose intravenous naloxone provides an alternative method of buprenorphine induction that limits the experience of withdrawal to a shorter time window compared to existing protocols.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.